You are here

Development of OCT Imaging Adapter for Interstitial Tissue Imaging

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA174261-01A1
Agency Tracking Number: R43CA174261
Amount: $299,724.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA12-088
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
116 Lowes Food Drive
Lewisville, NC 27023-
United States
DUNS: 967586376
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (314) 566-6376
Business Contact
Phone: (314) 566-6376
Research Institution

DESCRIPTION (provided by applicant): In this application, we propose to conduct research to advance our patented technologies that identify early evidence of cardiovascular (CV) injury upon the receipt of cardiotoxic chemotherapy for breast cancer patients. For these patients, the prevalence of cardiovascular events including heart failure (HF) is 18% - 22%, and represents the second leading cause of morbidity and mortality. We have identified a method to detect early evidence of myocellular injury which offers opportunities for early treatment so that these patients avoid permanent myocardial damage that causes HF. In this study, we propose to: 1) determine the utility of our analyses for identifying the myocellular injury associated with administration ofdoxorubicin. 2) determine the utility of our results to forecast future changes i left ventricular ejection fraction (LVEF) upon receipt of doxorubicin chemotherapy, and 3) determine the association between our results, LVEF and serum Troponin after receipt of doxorubicin chemotherapy. The results of this proposal will provide the data that is needed to develop this analytic model for the product that identifies the breast cancer patients who are the most susceptible to myocardial injury and LV dysfunctionsuch that targeted interventions can be started to reduce the impact of these CV events. For these patients, our product will provide an integrated system of quantitative and longitudinal tracking of CV injury. In the future, this product can be scaled toinclude other patient populations in need of surveillance for cardiomyopathy such as, other cancer survivors, diabetics, the obese, and patients with viral infections. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: In this application, we propose to advance the use of our novel imaging analysis tool so that breast cancer patients, who have suffered cardiovascular injury from their chemotherapy treatments, can be identified early, when their injury is still treatable. Cardiovascular injury is the second leading cause of morbidity and mortality for these women; however, if these patients are treated for their cardiovascular injuries before they develop heart failure their prognosis is greatly improved. In the future, this product can be expanded to include other patient populations in need of surveillance for early cardiac injury, such as, childhood and prostate cancer survivors, alcoholics, diabetics, the obese, and patients with HIV or other viral infections.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government